Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Johnson & Johnson has agreed to acquire Atraverse Medical, a medical devices business in the cardiovascular space, for an undisclosed amount. Atraverse Medical develops next-generation left-heart access and radiofrequency technology, including the HOTWIRE Transseptal Access System used for left atrium access during cardiac ablation procedures. The FDA-cleared radiofrequency guidewire and generator platform supports electrophysiologists with impedance-sensing automatic energy shutoff, compatibility with multiple sheaths, and improved tip visibility under intracardiac echocardiography. Johnson & Johnson acquisitions in healthcare M&A are expected to close in Q2 2026, subject to customary conditions, as an add-on acquisition that expands its cardiac ablation portfolio for atrial fibrillation and other cardiac arrhythmias.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026